Glycosaminoglycan Conjugation via Aldehyde Derivatization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for conjugating glycosaminoglycans (GAGs) with biologically active molecules, such as proteins and polypeptides, often result in irregular functionalization patterns, leading to variable biological activity, bioavailability, and immunogenicity, and lack control over the derivatization site, which compromises the protein's functionality and stability.
Innovation Solution
A process involving the derivatization of GAGs with aldehyde groups using a spacer molecule, followed by reaction with biologically active molecules, allowing for specific binding without altering the protein's structure or net charge, enabling the formation of monodispersed conjugates with improved solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional conjugation methods are used to attach polymers to proteins, then the polymer conjugation improves solubility and prolongs action, but the functionalization becomes irregular and polydispersed, leading to variable biological activity and immunogenicity
Solution Approach 1:
The patent introduces a preliminary derivatization step where GAGs are first modified with aldehyde groups before conjugation with proteins. This preliminary action creates a controlled reactive intermediate that enables subsequent site-specific conjugation, resolving the contradiction between prolonged action and functionalization regularity by establishing precision before the final conjugation event
Solution Approach 2:
The patent employs an aldehyde derivative of GAG as an intermediary species. This intermediary contains reactive aldehyde groups that can selectively form hydrazone bonds with amine groups on proteins under controlled conditions. The intermediary acts as a bridge between the GAG polymer and the protein, enabling precise control over conjugation sites while maintaining the solubility and prolonged action benefits
2Reliability
If PEGylation methods are used to modify proteins at specific sites, then the conjugates show improved efficacy and half-life, but the methods require complex multi-step processes and specific pH conditions that limit versatility
Solution Approach 1:
The patent creates a universal conjugation platform where GAGs can be derivatized with aldehyde groups that react with various amine-containing proteins under similar conditions. The method is not limited to specific protein types or sites, making it universally applicable to different therapeutic proteins while maintaining reliable conjugate efficacy without requiring protein-specific optimization of each conjugation protocol
3Quantity of substance
If GAGs are conjugated with therapeutic agents to improve solubility and bioavailability, then the conjugates show enhanced pharmacokinetic properties, but the derivatization may alter the protein's net charge and structure, compromising functionality
Solution Approach 1:
The patent implements local quality by targeting specific amine groups on proteins for conjugation rather than random modification throughout the protein structure. The aldehyde groups on GAGs preferentially react with accessible N-terminal or lysine amine groups, creating localized conjugation sites that improve solubility and bioavailability while preserving the overall protein structure and net charge distribution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves conjugates with enhanced efficacy, bioavailability, and specificity, maintaining the biological activity of the therapeutic agent while providing controlled release systems and targeted delivery through receptor interactions, avoiding immunogenic responses.
Implementation Method 1
reaction of the adduct obtained in phase a) or a1) with at least one biologically active molecule (TA) characterized in that it comprises a functional group capable of reacting with the aldehyde group
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.